Medical Affairs in 2025: A four-year future plan
CHAPEL HILL, N.C., May 31, 2021/PRNewswire/ -- The last decade has seen Medical Affairs move from a support function to what many view as the third leadership pillar in biopharma. Change has been constant. Moreover, the Covid-19 pandemic has triggered a tsunami of rapid technology and role changes for Medical Affairs.
In response, Medical Affairs leaders are asking the question: Where will Medical Affairs be in 2025 and how do we adapt to get there?
The study found that Guideline Organizations, Advocacy Groups and Payer Groups will become critical collaborators with Medical Affairs by 2025.
"Medical Affairs 2025: Where are we going? How do we get there?" is a 44-page study that probes evolving stakeholders, roles, tools, technologies, capabilities, value fronts, and structures. It further explores the direction of change and velocity of change.
- Explores how Medical Affairs will align its function and teams in the future and how it will coordinate with internal groups and support external stakeholders
- Examines what activities will be of primary value moving forward to 2025
- Identifies key external stakeholder targets for support
- Identifies key targets for the delivery of insights
The study engaged 74 executives from 57 leading life sciences companies. Chief Medical Officers and Medical Directors represent nearly 80% of the leaders who reflected on current Medical trends and future directions in this study.
To learn more about this report, download a complimentary report excerpt at https://www.best-in-class.com/rw86.htm
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.